Personalized treatment for IgA nephropathy and IgA vasculitis
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a kidney biopsy confirming IgA nephropathy or IgA vasculitis.
- You must have persistent protein in your urine, at least 0.5 grams per day, measured twice at least 4 weeks apart.
- Your kidney function (eGFR) must be 30 or above.
- You must have been on standard blood pressure and kidney protection medication (ACEI or ARB) for at least 4 weeks.
- You must be planning to start or have already started Nefecon or telitacicept for 2 weeks or less.
- You must not have certain other kidney diseases, active infections, severe gastrointestinal issues, or have been on certain immune-suppressing drugs recently.
- You must not have had active cancer or organ transplantation.
- Your blood counts and liver function need to be within acceptable limits.
- You cannot be pregnant, breastfeeding, or planning to conceive or donate sperm during the trial.
- You must not have severe high blood pressure that cannot be controlled.
- You must not be obese or underweight (BMI must be between 18.5 and a higher limit).
- You must not have allergies to human-derived products.
- You must not be on drugs that could harm your kidneys during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.